Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.

摘要: Over the past two decades, a number of chemical entities have been investigated in continuing quest to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) cancer cells and some undergone clinical trials, but currently none are use. Unfortunately, most these agents suffer clinically from their intrinsic toxicity or undesired effects on pharmacokinetics accompanying anti-cancer drugs. An acridonecarboxamide (GF120918), Imidazo acridone (C1311) timethylene derivative 1,3-bis(9-oxoacridin-10-yl)-propane (PBA) already shown be among group compounds known modify P-gp MDR cancer. In recent it has identified that various N10-substituted acridones can by selectively inhibiting associated protein (MRP) calmodulin dependent cyclic AMP phosphodiesterase. This article envisages drugs being developed for treating especially derivatives which author.